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Background: Several cross-sectional studies have estimated that the prevalence of femoroacetabular impingement
(FAI) ranges from 14-17% among asymptomatic young adults to almost 95% among competitive athletes. With FAI,
there is abnormal contact between the proximal femur and the acetabulum, resulting in abnormal mechanics with
terminal motion such as hip flexion and rotation. This condition results from bony anomalies of the acetabular rim
(Pincer) and or femoral head/neck junction (CAM) and typically causes hip pain and decreased hip function. The
development of hip pain potentially serves as an indicator for early cartilage and labral damage that may result in
hip osteoarthritis. Although surgical correction of the misshaped bony anatomy and associated intra-articular soft
tissue damage of the hip is thought to improve hip pain and alter the natural history of degenerative disease, the
supportive evidence is based upon low quality observational studies. The Femoroacetabular Impingement RandomiSed
controlled Trial (FIRST) compares outcomes following surgical correction of the impingement morphology (arthroscopic
osteochondroplasty) with/without labral repair versus arthroscopic lavage of the hip joint in adults aged 18 to 50
diagnosed with FAI.
Methods and design: FIRST is a multi-centre, randomized controlled trial with a sample size of 220 patients.
Exclusion criteria include the presence of hip syndromes, previous surgery or trauma to the affected hip, and
significant medical comorbidities. The primary outcome is pain and the secondary outcomes include patient
function, quality of life, complications, and cost-effectiveness – all within one year of follow-up. Patients are
stratified based on centre and impingement sub-type. Patients, outcome assessors, data analysts, and the Steering
Committee are blinded to surgical allocation. Using an intention-to-treat approach, outcome analyses will be
performed using an analysis of covariance and descriptive statistics.
Discussion: Symptomatic FAI is associated with chronic hip pain, functional limitations, and secondary
osteoarthritis. Therefore, optimizing treatment has the potential to improve the lives millions of young, active
persons who are diagnosed with this condition. Few orthopaedic surgical trials have similar potential to shift the
paradigm of care dramatically towards (or away) from surgical bony and soft tissue interventions.
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Trial registration: The FIRST trial is registered with clinicaltrials.gov (NCT01623843).
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Femoroacetabular impingement (FAI) is a recently de-
scribed condition that causes hip pain in the young
adult. Some cross-sectional studies have estimated that
the prevalence of hip impingement ranges from 14-17%
among asymptomatic young adults to almost 95%
among competitive athletes [1-3]. FAI occurs as a result
of a size and shape mismatch between the femoral head
(ball) and the acetabulum (socket). FAI is typically classi-
fied into two subtypes; CAM type (a misshaped femoral
head) or Pincer type (an over covered or deep socket)
(Figure 1). Most patients have a combination of both
types of impingement (Mixed) [4]. With FAI, the abnor-
mal femoral head-neck junction and acetabular rim of
the hip joint collide or “impinge” during movements
such as hip flexion and rotation [5]. Typically, patients
with this condition may experience hip pain and loss of
hip function. The development of hip pain in this manner
is believed to result in early cartilage and labral damage,
potentially resulting in hip osteoarthritis [5].
Although no definitive long term longitudinal studies
exist, the current literature is suggestive of a relationship
between longstanding FAI and hip osteoarthritis [6].
Agricola and colleagues found that an alpha angle greaterFigure 1 Femoroacetabular impingement sub-types (from http://www.kethan 83 degrees (angle greater than 50 is used to describe
CAM impingement) resulted in an odds ratio 9.66 for the
development of hip osteoarthritis within 5 years follow-up
[7]. Clohisy et al. also found that approximately one third
of patients with hip joint failure secondary to osteoarthritis
had deformities related to FAI [8].
This association has fuelled a more aggressive approach
to treating the painful and dysfunctional hip with surgical
treatment to correct abnormalities of FAI. Colvin et al. re-
ported an 18-fold increase in hip arthroscopic procedures
between 1999 and 2009 amongst orthopaedic graduates
[9]. Likewise, Bozic et al. demonstrated a 600% increase in
hip arthroscopy amongst orthopaedic surgeons completing
their Board examinations in the United States (US) from
2006 to 2010 [10]. More recently, estimates suggest that
the rate of hip arthroscopy procedures will double over a
5 year span from 30,000 in 2008 to over 70,000 in 2014 in
the US alone [11]. Increasingly, academic institutions in
the US, Canada, and worldwide are employing orthopaedic
surgeons who have expertise in hip impingement surgery,
and the publicity from popular athletes having hip surgery
for FAI continues to drive the mass demand for surgical
intervention [12]. A corresponding dramatic increase in
health care costs is expected for these procedures.vinneeld.com/2011/training-around-femoroacetabular-impingement).
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Patients with FAI often fail non-operative interventions,
including rest, physical therapy, oral anti-inflammatories,
and hip injections [13]. Surgical intervention usually in-
volves correcting the existing deformities by reshaping the
ball and socket (“osteoplasty” or “rim trimming”) so that
they fit together more easily while repairing any other
existing soft tissue damage in the hip joint (e.g. labral
repair). FAI is managed with open surgical techniques
(surgical hip dislocation) as well as keyhole or arthroscopic
surgical techniques. Although several reviews have shown
no significant differences in clinical outcome with the use
of either technique, the arthroscopic approach is becom-
ing increasingly popular due to its minimally invasive
technology and out-patient basis of the surgery. Although
correction of the misshaped bony anatomy and associated
intra-articular soft tissue damage of the hip is thought to
appease impingement and improve pain and function, the
evidence is based upon observational studies.
We conducted several systematic reviews of the avail-
able literature to identify optimal treatment strategies
[14-19]. In a systematic review of two electronic databases
(MEDLINE and EMBASE), we identified 298 relevant
studies on the topic of FAI between 2005 and 2010. Over
this 5 year period, there was an approximate five-fold
increase in the number of FAI related publications. The
majority of publications consisted of case series with a
notable absence of clinical trials [17].
In another review of the outcomes of surgical deformity
correction (osteoplasty), of 1,103 potentially relevant
studies, 14 fulfilled our eligibility criteria. All studies
were observational designs (12 case series, 1 prospective
cohort, and 1 case–control study). Correction resulted in
significant improvements in patients’ hip pain and func-
tion [15]. In another review, we evaluated the impact of
labral repairs on patient outcomes [19]. We identified six
eligible observational studies (5 retrospective comparative
designs, 1 prospective cohort) involving 490 patients. Four
studies reported that labral repair had greater postopera-
tive improvements in functional scores compared to labral
debridement alone. Five studies reported statistically sig-
nificant improvements with labral repair [19].
In a survey of 200 surgeon members of the Canadian
Orthopaedic Association who treat young adults with hip
pain, considerable disparity in preferences for surgical
treatment of FAI existed, with 50% endorsing both bony
and soft tissue procedure, 2% soft tissue only, 10% bony
procedures only, and 24% unsure about any surgical
option. In contrast, surgeons achieved near consensus
(90%) that there is a need for a well conducted randomized
controlled trial (RCT) to evaluate the efficacy of current
surgical interventions [20].
The significant benefits in outcome purported to arise
from surgical management of FAI (osteochondroplasty)are solely driven by observational studies, often with no
controls. Given the growing awareness of the evidence
gap and lack of clear consensus on the utility of FAI sur-
gery fuelled the design and start-up activities of the
Femoroacetabular Impingement RandomiSed controlled
Trial (FIRST) - a multicenter RCT to evaluate operative
management of FAI. There is a critical need to confirm,
or refute, this data with a RCT to overcome the biases
associated with lack of randomization, lack of conceal-
ment, lack of blinding and lack of independence in out-
come assessment.
Study objectives
The primary research objective is to assess whether
surgical correction of the impingement morphology
(arthroscopic osteochondroplasty) with/without labral
repair, in adults aged 18 to 50 diagnosed with FAI, provides
decreased pain at 12 months compared to arthroscopic
lavage of the hip joint as measured by a Visual Analog
Scale (VAS) [21-23].
The secondary research objectives are to assess whether
arthroscopic osteochondroplasty with/without labral re-
pair, in adults aged 18 to 50 diagnosed with FAI, provides
improved patient outcomes at 12 months compared to
arthroscopic lavage of the hip joint including:
1. Functional outcomes as measured by the Hip
Outcome Score (HOS) [24]
2. Generic physical and mental health as measured by
the Short Form-12 (SF-12) [25]
3. Impact of hip-specific disease on function and
lifestyle in the young, active patient as measured by
the International Hip Outcome Tool (iHOT-12) [26]
4. Health utility as measured by the EuroQol (EQ-5D)
[27]
5. Urinary and sexual function as measured by the
International Consultation on Incontinence
Questionnaire - Male/Female Lower Urinary Tract
Symptoms (ICIQ-MLUTS/FLUTS), the International
Index of Erectile Function (IIEF), and the Female
Sexual Function Index (FSFI) [28-31]
6. Complications including additional surgery,
infection, reduced range of motion, and other
adverse events
7. Costs and health resource utilization.
Methods/design
Overview of study design
FIRST is an ongoing multicenter, blinded RCT of 220
patients who have been diagnosed with FAI and are se-
lected for surgical intervention. Patients are recruited from
experienced hip surgeons practicing at the multiple par-
ticipating sites based both nationally and internationally.
Study personnel monitor critical aspects of perioperative
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related quality of life, health utility, cost-effectiveness, and
will independently adjudicate revision surgeries and other
complications over 12 months. Methods Centre ethics
approval was obtained from the Hamilton Integrated
Research Ethics Board (REB #12-396).
Patient selection
Eligibility criteria
We have broad inclusion criteria in place to improve the
feasibility of this trial, as well as patient compliance. All ex-
cluded patients will be logged for verification of the
generalizability of the results. The inclusion criteria are: 1)
adult men or women ages 18 to 50 years, 2) hip pain for
greater than 6 months with no relief from non-operative
means (physiotherapy, non-steroidal anti-inflammatory
medication, rest), 3) documentation of failed physiotherapy,
including core conditioning of the hip, back, and abdomen,
4) CAM or Mixed Type FAI as diagnosed on x-rays and
magnetic resonance imaging (MRI) or magnetic resonance
arthrogram (MRA), 5) temporary relief from an intra-
articular hip injection, 6) provision of informed consent
from the participant, and 7) ability of the participant to
speak, understand and read in the language of the clinical
site.
The exclusion criteria are: 1) previous inclusion of the
participant in a study involving FAI, 2) evidence of hip
dysplasia (centre edge angle less than 20), 3) presence of
advanced hip osteoarthritis (Tonnis Grade 2 or 3) [32],
4) presence of other hip syndromes (concurrent non-FAI
related pathology), 5) previous trauma to the affected
hip, 6) previous surgery on the affected hip or contralat-
eral hip, 7) severe acetabular deformities (e.g. acetabular
protrusion, coxa profunda, circumferential labral ossifi-
cation) [33], 8) immunosuppressive medication use, 9)
chronic pain syndromes, 10) significant medical co-
morbidities (requiring daily assistance for activities of
daily living; ADLs), 11) history of paediatric hip disease
(Legg-Calve-Perthes; slipped capital femoral epiphysis),
12) ongoing litigation or compensation claims secondary
to hip problems, and 13) any other reasons given, in the
surgeon’s judgement, to exclude the patient.
Patient recruitment and screening
The FIRST pilot study recruited 50 patients in one year
at two centres in Canada and Finland, providing feasibil-
ity data and allowing for greater precision for estimates
of recruitment and the definitive sample size calculation.
We are planning to expand to 10 sites across Canada,
Finland, Denmark, and the USA. The first definitive trial
patient was randomized on 23 October 2014 Enrollment
is ongoing at the time of publication and is expected to
be completed by December 2017. All patients presenting
to participating surgeons with diagnosed FAI amenableto arthroscopic surgery are screened for participation in
the FIRST trial. Such patients are classified as: 1) excluded
(if they do not meet the eligibility criteria); 2) missed
(presumed eligible but missed due to error or staff
availability); or 3) included (eligible and randomized).
Study personnel obtain informed consent from all eli-
gible patients.
Randomization
We use a centralized 24 hour computerized randomization
system that allows for automated internet based
randomization to allocate patients to the control or
intervention group in random block sizes of 4 and 8
prior to surgery. Using this randomization system ensures
concealment of treatment allocation [34]. We stratify
patients based on centre and impingement sub-type
(CAM or Mixed).
Study interventions
Osteochondroplasty
Patients in the intervention group (osteochondroplasty
with/without labral repair) have an initial hip evaluation
using hip arthroscopy. Three standard hip arthroscopy
portals (antero-lateral, mid anterior, distal antero-lateral)
are used during the entire procedure to assess and treat
the patient. After establishing standard portals, an inter-
portal capsulotomy is completed to allow for complete
evaluation of the central compartment of the hip. In the
central compartment, significant and obvious labral tears
and cartilage damage are addressed (repair or debride-
ment). The labrum is repaired if mechanically unstable
once probed with visible displacement or chondrolabral
separation. The acetabular rim is evaluated and any evi-
dent Pincer lesion is resected using an arthroscopic burr
under fluoroscopic guidance. Following this resection,
the labrum may be re-fixated only if the criteria for
labral instability is met. Following this, a limited capsu-
lotomy is completed along the head-neck junction of the
femoral neck to allow for visualization and treatment of
the impingement lesion in the peripheral compartment.
Intraoperative fluoroscopy is used once more to guide
the osteochondroplasty and resection of the impinge-
ment lesions [21,22,35].
Arthroscopic lavage (Control)
Patients in the control group (lavage) have the same
three hip portals with limited capsulotomy allowing for
a complete assessment of the central and peripheral
compartments. The participant has a diagnostic arthros-
copy and lavage of the hip joint with three litres of normal
saline. No osteochondroplasty or rim resection is com-
pleted in the control group. No instruments are used to
treat minor cartilage or labral damage. The labrum is only
repaired if mechanically unstable once probed with visible
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may be re-fixated only if the criteria for labral instability is
met.
During the FIRST pilot phase, of 22 patients random-
ized to the control arm, only one patient required a large
amount (>5 cm3) of labral debridement, providing re-
assurance of general compliance with the control arm
protocol.
Standardization of postoperative care
Postoperatively, we standardize pain management, pro-
tected weightbearing, venous thromboprophylaxis, and
physiotherapy. Any deviations from the standardized
protocol are documented by the blinded outcome
assessors.
Surgeon expertise and standardization of procedures
We expect all surgeons involved to have completed at
least 30 hip arthroscopic cases, as our prior systematic
review suggests that is a critical number of cases to
meet a learning curve and decrease complications [14].
Participating surgeons have a standardized video and
laboratory demonstration available to them to standardize
the surgical techniques for all participants [36]. In
addition, all investigators are provided with a standardized
postoperative care protocol [37].
Study outcomes
Primary outcome
The primary outcome is the change in pain scores be-
tween intervention and control patients at 12 months, as
rated using a Visual Analog Scale (VAS) [22,23].
The VAS is one of the most frequently used pain rating
scales in clinical practice and research [21]. The VAS is a
validated unidimensional scale that is easy to use, requires
no verbal or reading skills, and is sufficiently versatile to
be employed in a variety of settings [38-40].
Secondary outcomes
Secondary outcomes include the change in functional
outcome, health utility, and quality of life scores using
self-administered and interview-administered question-
naires. Questionnaires include a generic health status
measurement instrument (SF-12), hip function question-
naires (HOS, iHOT-12), a health utility measure (EQ-
5D), and urinary (ICIQ-MLUTS/FLUTS) and sexual
function questionnaires (IIEF/FSFI) [26,28-31,41-45].
We will also collect patient cost data, report differences
in complication and revision surgery rates, as well as
secondary procedures such as anti-inflammatory hip
injections.
The SF-12 may be self or interview-administered and
will help document general health status as well as the
burden of illness that FAI presents [25]. The HOS is aself-administered hip score that was designed to capture
hip function and outcomes following surgical therapies
such as arthroscopy [24]. The HOS has been shown to
have the greatest clinimetric evidence for use in patients
with FAI or labral tears [46,47]. The iHOT-12 is a
shorter version of the iHOT-33 designed to be easier to
complete in routine clinical practice to measure both
health-related quality of life and changes after treatment
in young, active patients with hip disorders [26]. This
questionnaire has been shown to be valid, reliable, and
responsive to change [26]. The EQ-5D is a standardized
instrument for use as a measure of health outcome [27].
The EQ-5D comprises five dimensions of health (mobility,
self-care, usual activities, pain/discomfort, and anxiety/de-
pression). The EQ-5D has been used in previous studies
involving patients with hip pain and has been extensively
validated [48,49]. Our decision to the use EQ-5D was
based upon our interest in collecting health utility data for
a formal cost-effectiveness analysis.
Because arthroscopy of the hip is more technically
challenging than for other joints due to the deep-seated
nature of the hip joint, the surrounding soft tissue enve-
lope, and the encapsulated ball and socket configuration,
any excessive, inadequate or improperly applied traction
could result in compression injury to the perineum, pu-
dendal neuropraxia, and skin complications, sometimes
causing urinary and/or sexual dysfunction [50-53]. The
two validated questionnaires selected that pertain to
male and female urinary symptoms are gender specific
variations of the ICIQ-MLUTS (male) and ICIQ-
FLUTS (female). These are validated patient-completed
questionnaires, which evaluate lower urinary tract symp-
toms (LUTS), as well as quality of life [28,29]. Both
questionnaires have demonstrated validity, reliability and
responsiveness internally and externally. The FSFI is a
brief psychometrically sound and reliable tool that
assesses female sexual function, and has proven ability
to discriminate between clinical and nonclinical popula-
tions [30]. The FSFI is also designed to measure the
impact of sexual function on quality of life [30]. The
IIEF is a brief self-administered questionnaire assessing
sexual experience within the past 4 weeks, consisting of
15 questions designed to address 5 relevant aspects of
male sexual function; specifically erectile function, sexual
desire, orgasmic function, intercourse satisfaction and
overall satisfaction [31,54]. This instrument is psycho-
metrically sound with high sensitivity and specificity and
has been validated for administration in research and
clinical settings across cultures with linguistically vali-
dated versions [31,54].
The questionnaires are validated for many of the
countries where our trial centres are located. All ques-
tionnaires will be translated to the site-specific primary
language. We will record all changes in pain medication
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events (Table 1). We will also conduct a cost analysis
based on collected cost data (using a patient cost diary)
and the health utility questionnaire.
Study follow-up
Patients undergo baseline evaluation with regular
follow-up visits at 2 weeks, 6 weeks, 3 months, 6 months,
and 12 months postoperatively. This follow up schedule
is in accordance with the current practice at each trial
centre and does not require extra visits or costs to the
patients. Patients who are unable to attend the follow-up
appointments will be contacted by phone to complete
the questionnaires. The full study process is shown in
Figure 2.
Our decision to follow patients to one year represents
a practical and trial cost compromise between earlier
perioperative outcomes and longer term sequelae of FAI
(5 years or more). The current literature is limited by
the reporting of short term outcomes with follow-up
ranging from 6 months to 5.2 years [55]. Outcomes
between one year and 5 years have been shown to be
not significantly different [56,57]. Further, we surveyed
experts in FAI surgery in North America and identified
that most surgeons expect maximum improvement by
12 months following surgery [20]. Thus, it is unlikelyTable 1 FIRST schedule of events
Assessment Screenin
Screening form X
Informed consent X
Randomization form
Baseline characteristics form
Hip characteristics form
Surgical form
Arthroscopic findings form
Perioperative form
Follow-up form
Complications form (if required)
Pain medication log (if required)
X-rays and/or MRI X
Pain Visual Analog Scale (VAS)
Hip Outcome Score (HOS)
Short Form 12 (SF-12)
International Hip Outcome Tool (iHOT-12)
EuroQol 5D (EQ-5D)
International Consultation on Incontinence Questionnaire Male/
Female Lower Urinary Tract Symptoms (ICIQ-MLUTS/FLUTS)
International Index of Erectile Function (Male) (IIEF)
Female Sexual Function Index (FSFI)that follow-up beyond one year will yield a differential
treatment effect from FAI surgery versus controls, and
the results will remain clinically meaningful.
Protecting against sources of bias
We have implemented multiple methods for protecting
against bias. We conceal randomization, maximize possible
blinding, utilize strategies to limit loss to follow-up and
crossovers, and objectively adjudicate patient outcomes.
Blinding
Patients, outcomes assessors and data analysts are
blinded to patient allocation by limiting their access to
surgical records and postoperative x-rays. Blinding of pa-
tients is feasible because their postoperative care
(physiotherapy etc.) does not differ between treatment
groups. To participate in the trial, patients provide con-
sent that limits their access to postoperative x-rays or
surgical notes until the follow-up period for the trial is
complete.
Maximizing patient follow-up
We have implemented several procedures to limit loss of
follow-up, including excluding individuals who are likely
to present problems with follow-up, obtaining extensive
contact information from each consented patient, havingg Enrolment
(Baseline)
Surgery 2
Weeks
6
Weeks
3
Months
6
Months
12
Months
X
X
X
X
X
X
X X X X X
(X) (X) (X) (X) (X) (X)
(X) (X) (X) (X) (X) (X)
X X
X X X X X X
X X X X X X
X X X X X X
X X X X X X
X X X X X X
X X X
X X X
X X X
Follow-up #4: Complete questionnaires 6 months postop
(between 5 and 7 months). To be completed in clinic.
Follow-up #3: Complete questionnaires 3 months postop
(between 2 and 4 months). To be completed in clinic.
Follow-up #2: Complete questionnaires 6 weeks postop
(between 5 and 7 weeks). To be completed in clinic.
Follow-up #1: Complete questionnaires 2 weeks postop
(between 1 and 3 weeks). To be completed in clinic.
Screen all patients presenting with 
Femoroacetabular Impingement
Baseline: Complete questionnaires pre-and postop.
To be completed in clinic
Exclude patients based on the following criteria:
1) Previous inclusion in a study involving FAI; 2) 
Evidence of hip dysplasia (centre edge angle less than 
20); 3) Presence of advanced hip osteoarthritis (Tonnis 
Grade 2 or 3); 4) Presence of other hip syndromes 
(concurrent non-FAI related pathology); 5) Previous 
trauma to the affected hip; 6) Previous surgery on the 
affected hip; 7) Severe acetabular deformities; 8) 
Immunosuppressive medication use; 9) Chronic pain 
syndromes; 10) Significant medical co-morbidities 
(requiring daily assistance for ADLs); 11) History of 
paediatric hip disease (Legg-Calve-Perthes; slipped 
capital femoral epiphysis); 12) Ongoing litigation or 
compensation claims secondary to hip problems; 13) Any 
other reason.
Option for 
telephone follow-up 
when patient is 
unable to attend an 
in-clinic visit.
Include patients based on the following criteria:
1) Age 18-50; 2) Hip pain for greater than 6 months 
with no relief from non-operative means; 3) 
Documentation of failed physiotherapy, including 
core conditioning of the hip, back, and abdomen;
4) CAM or Mixed Type FAI as diagnosed on x-
rays and MRI/MRA; 5) Temporary relief from an 
intra-articular hip injection; 6) Informed Consent 
from participant; and 7) Ability to speak, 
understand, and read in the language of the clinical 
site.
Follow-up #5: Complete questionnaires 12 months postop
(between 11 and 13 months). To be completed in clinic.
Figure 2 FIRST process overview.
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visits, and ensuring that follow-up visits coincide with
normal surgical clinic visits (Table 2). Using these strat-
egies during the pilot study, we were able to achieve a
95% follow-up rate.
Minimizing crossovers
Crossovers are extremely unlikely between the osteo-
chondroplasty and lavage groups because both involve
arthroscopic approaches and the same surgeon will be
performing all procedures at each site. Any patients who
do crossover will be analyzed in the group to which they
were randomized, maintaining the intention to treat ap-
proach we plan to use for the analyses. There were nocrossovers for the first 50 patients in the pilot phase of
the trial, supporting our assertion that crossovers will be
rare.
Adjudication
An independent, blinded Adjudication Committee will
review patient eligibility (e.g. preoperative radiographic
alpha angle [15,58,59]), intraoperative arthroscopic find-
ings, and all reported complications. The committee is
comprised of three orthopaedic surgeons with expertise in
hip surgery and adjudication. All centres submit x-rays
and/or MRI images and relevant hospital records to be
included in the adjudication process. Any disagreements
between the Adjudication Committee members will be
Table 2 FIRST enrolment and follow-up enhancement strategies
Before the study
begins
At screening At baseline During the study For participants who are
difficult to contact
• Formally train
clinical research
coordinators on
how to reduce
loss to follow-up
• Let participants know what
information will be collected
and how their information
will be used
• Obtain several personal
contacts on a locator
form, including friend or
family and employment
contacts to assist in
locating participants later
• Provide participant with a
choice of email, phone,
and/or clinic visits for
convenience
• Repeatedly search for
updated information or try
previously disconnected
phone numbers
• Ensure the
survey area is
private and
comfortable
• Let participants know that
the study might help other
patients in similar situations
to enhance their motivation
to participate
• Ensure each locator form
is signed by the
participant to ensure a
thorough understanding
and to give written
consent to contact listed
individuals
• Be flexible on scheduling
in-clinic visits to allow for
scheduling issues to be
resolved
• Search local phone
directories, contact alternate
contacts, try to contact
patients from a different
phone number or at a
different time of day
• Develop a
locator protocol
to guide efforts
to locate
patients for
follow-up visits
• Be explicit with the
participant about the
follow-up procedures
including providing specific
information to the participant
about when to expect contact
from the study staff, how
often, and what type of
contact (email, in-person,
telephone, etc.)
• Ensure informed consent
is conducted in an
appropriate manner,
including using examples
and explanations that are
accessible to a lay
audience
• Ensure participants can easily
contact the study staff by
providing them with
materials on which the study
toll-free number was printed,
such as business cards,
appointments cards,
brochures, or study
promotional materials
• Hold regular staff meetings
to brainstorm ideas about
how to find some of the
participants who are the
most difficult. This will also
increase staff motivation for
locating hard-to-find
participants
• Routinely verify contact
information
• Study personnel will log all
attempts to contact each
participant and the outcome
of each attempt
• The methods centre will
conduct random site audits
to verify that all precautions
are being taken to secure
data
• The methods centre will
conduct extensive data entry
audits and verifications,
weekly data reports,
recruitment reports, and
contact tracking reports
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cannot initially be reached, additional information will be
requested from the participating site to clarify areas of
uncertainty.Sample size calculation
We powered the FIRST trial to detect a minimal clinically
important improvement (MCII) in the VAS pain score
(improvement of at least 13 points) between hip osteo-
chondroplasty and lavage. The estimates of MCII were
based upon Norman et al. and estimates from our pilot
clinical trial [60]. To achieve 80% study power and using
at two-sided Type I error rate (5%), our trial requires 73
patients per study arm.
For the secondary outcomes, we set the two-tailed
Type I error rate to 1% to account for multiple compari-
sons. We consider an important difference in the SF-12to correspond to a moderate effect as reported by Cohen
[61], as well as a minimally important difference (MID)
in the SF-12 as reported by Ware [62]. In both cases, the
value is at least half the standard deviation, equivalent to
a 4-point difference in score. Specifying an alpha level of
0.01 and a beta of 0.20 (study power = 0.80), we require a
sample of at least 192 patients (96 per group) to ensure
detection of a half standard deviation in improvement.
The HOS, under the assumption of a MID of 13 points,
will require 93 patients per treatment group. The iHOT-
12 will require 85 patients per group given the MID of 6.1
from Mohtadi et al.[47].
Therefore, for adequate study power across all our
planned outcome measures, we will need to recruit and
follow 192 patients. To account for potential loss to follow
up (5%) and potential crossovers (5%), FIRST will recruit
107 patients per treatment arm, rounded to 220 patients
in total.
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Primary analyses
We will adopt the intention to treat principle for all ana-
lyses—that is, patients will be retained in the groups to
which they were randomized. The baseline characteristics
of the patients will be summarized by group, reported as a
mean (standard deviation) or median (first quartile, third
quartile) for continuous variables and count (percent) for
categorical variables. We will use an analysis of covariance
(ANCOVA) to compare the mean pain scores (VAS) at
12 months post-surgery adjusting for baseline scores. The
treatment effect will be quantified with an absolute differ-
ence in rate of pain reduction with the associated 95%
confidence interval (CI) and p-value. All p-values will be
reported to 3 decimal places with those less than 0.001
reported as p < 0.001. The criterion for statistical signifi-
cance will be set at alpha = 0.05. Multiple regression
models will be used to determine variables and factors
related to improvement in pain and quality of life scores.Secondary analyses
We will estimate the effect of arthroscopic osteochon-
droplasty (intervention) versus lavage (control) on FAI
patient quality of life (SF-12), function (HOS, iHOT-12),
health outcome (EQ-5D), and sexual/urinary function
(ICIQ-MLUTS/FLUTS, FSFI, IIEF) at 12 months with
ANCOVA using the following covariates: 1) baseline
scores and 2) impingement sub-type. We will use multiple
imputation to handle missing data to enable an intention
to treat analysis [63]. The results will be reported as means
with 95% CIs. We will use the Bonferroni method to
adjust the p-value for multiple secondary outcomes.Sensitivity and subgroup analyses
We will perform the following sensitivity analyses: 1)
centre-effects: we will redo both primary and secondary
analyses adjusting for centre as fixed and random-
effects; 2) per-protocol analysis: we will also redo the
analyses including patients who received the interventions
as allocated; and 3) adjusted analyses: we will perform
adjusted analyses to address any residual baseline imbal-
ance between groups [64].
We plan to conduct a subgroup analysis comparing the
treatment effects in patients with severe (alpha angle
greater than 83 degrees), moderate (alpha greater than 60
degrees), and mild (alpha angle of less than 60 degrees)
impingement at baseline. Surgeons often describe FAI de-
formity in ranges from mild, moderate, to severe [65]. As
such, an analysis of outcomes based on the severity of the
deformity would be informative to both patients and sur-
geons. We plan to use ANCOVA models and include
treatment by subgroup interactions to assess whether themagnitude of the treatment effect is significantly different
between subgroups [7,65,66].
Data management
The Case Report Forms (CRFs) are the primary data col-
lection tool for the study. An Electronic Data Capture
system (iDataFax) is being used to submit data to the
Methods Centre located at McMaster University. Upon
receipt of the data, the personnel at the Methods Centre
make a visual check of the data and query all missing,
implausible, and inconsistent data.
Data safety and monitoring committee
The purpose of the Data Safety and Monitoring Commit-
tee (DSMC) is to advise the FIRST Investigators regarding
the continuing safety of the trial participants. The DSMC
is comprised of a clinical expert with prior trial experience,
a clinical trial methodologist, and a biostatistician. All
members are independent of the trial investigators, and
have neither financial nor scientific conflicts of interest
with the trial.
Ethical considerations
All patients included in FIRST will sign a site-specific,
Ethics Board-approved consent form that describes this
study and provides sufficient information for patients to
make an informed decision about their participation. All
participating centres must obtain Ethics Board approval
from their institution for the study protocol, the consent
form template, the CRFs, and any additional protocol
amendments. Any protocol amendments will be com-
municated to the site investigators, the Ethics Board,
trial participants, and trial registries as necessary.
Information about study patients will be kept confiden-
tial and will be managed in accordance with the following
rules: 1) All study-related information is stored securely at
the clinical site, 2) All study patient information is stored
in locked file cabinets and is accessible only to study
personnel, 3) All CRFs are identified only by a coded
patient number and initials, 4) All records that contain
patient names, or other identifying information, are
stored separately from the study records that are identi-
fied only by the coded patient number and initials, and
5) All local databases are password protected.
Discussion
The rationale for the FIRST trial includes: 1) a growth in
popularity during the last 10 years in the surgical man-
agement of FAI; 2) global uncertainty in the surgical
community regarding efficacy of surgical management of
FAI; 3) a lack of compelling RCTs evaluating the efficacy
and safety of FAI surgery on patient important out-
comes; 4) a large body of preparatory research including
systematic reviews, surveys, and agreement studies; and
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finitive surgical trial addressing FAI based upon our
highly successful pilot phase (n = 50 patients).
The FIRST trial is one of the first RCTs to evaluate
the potential benefits in outcome purported to arise
from the surgical management of FAI. This trial will
overcome many of the limitations and associated biases
of the current literature. The trial sample size (N = 220)
was calculated based on pilot study data to ensure there
will be sufficient statistical power to detect differences
across several patient important outcomes, including
pain, function, and quality of life. Our pilot has also
demonstrated feasibility through our ability to recruit
patients efficiently; investigator compliance with key
aspects of the protocol; maintenance of data quality;
maintenance of high follow-up rates; and the research
team’s ability to organize and coordinate trial procedures
in a multinational trial. Furthermore, the FIRST trial has
methodological safeguards including the use of a central-
ized system to randomize patients; blinding patients, out-
come assessors, data analysts, and the Steering Committee;
standardization and documentation of peri-operative care;
the use of strategies to limit loss to follow up; and adju-
dication of trial events by an independent Adjudication
Committee.
As with any surgical RCT, a limitation of the FIRST trial
is that surgeons cannot be blinded to the treatment alloca-
tion. Given that FAI is a relatively newly diagnosed condi-
tion, there are few expert surgeons that identify and treat
it, and many have differing opinions on the ideal surgical
approach and the amount of soft tissue repair required for
these patients. We have put protocols in place to limit
possible inconsistencies across sites by standardizing and
monitoring critical aspects of operative and peri-operative
care, including preclusion of extensive repair in patients
allocated to the control group (unless deemed necessary
by the participating surgeon), pain management, protected
weight bearing, venous thromboembolism thrombopro-
phylaxis, and physiotherapy. We will also only invite
surgeons who are experts in FAI surgery to participate
in this trial.
The 5-fold increase in literature promoting the surgical
management of FAI (2005–2010) has focused on tech-
niques and early outcomes, predominantly through case
series lacking controls and bias reducing measures [16]. It
remains plausible that, in the absence of high quality com-
parative evidence, the increase in FAI procedures, largely
driven by observational studies, may result in unnecessary
surgery, potential harm, and increased health care costs
[11]. With an estimated FAI prevalence of 14-17% in the
general North American population (at least 74 million
persons), optimizing treatment has the potential to im-
prove the lives of millions of young, active persons who
are diagnosed with hip impingement [1,2]. Improvingoutcomes will directly reduce the economic burden of
FAI. Few orthopaedic surgical trials have similar potential
to shift the paradigm of care dramatically towards (or
away) from surgical bony and soft tissue interventions,
likely leading to changes in sports medicine practice.
Abbreviations
ANCOVA: Analysis of Covariance; CI: Confidence Interval; CRF: Case Report
Form; DSMC: Data Safety and Monitoring Committee; EQ-5D: EuroQol 5
Dimensions; FAI: Femoroacetabular Impingement; FIRST: Femoroacetabular
Impingement RandomiSed controlled Trial; FSFI: Female Sexual Function
Index; HOS: Hip Outcome Score; ICIQ-FLUTS: International Consultation on
Incontinence Questionnaire Female Lower Urinary Tract Symptoms; ICIQ-
MLUTS: International Consultation on Incontinence Questionnaire Male
Lower UrinaryTract Symptoms; IIEF: International Index of Erectile Function;
iHOT-12: International Hip Outcome Tool; MCII: Minimal Clinically Important
Improvement; MID: Minimally Important Difference; MRA: Magnetic
Resonance Arthrogram; MRI: Magnetic Resonance Imaging; RCT: Randomized
controlled trial; SF-12: Short Form-12; VAS: Visual Analog Scale.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
OA, MB, AB, TJ, VM, DN, MS, GS, DW, and LT made substantial contributions
to conception and design, or acquisition of data, or analysis and
interpretation of data. OA, NS, MS, SS, and MB have been involved in
drafting the manuscript or revising it critically for important intellectual
content. All authors read and approved the final manuscript.
Writing Committee: Olufemi Ayeni, Nicole Simunovic, Matti Seppänen, Daniel
Whelan, Sheila Sprague, Mohit Bhandari.
Steering Committee: Olufemi Ayeni (Chair), Mohit Bhandari (Co-Chair),
Asheesh Bedi, Teppo Järvinen, Volker Musahl, Douglas Naudie, Matti
Seppänen, Gerard Slobogean, Lehana Thabane.
Methods Centre (McMaster University): Olufemi Ayeni (Principal Investigator);
Sheila Sprague (Research Program Manager); Nicole Simunovic (Research
Coordination); Diane Heels-Ansdell, (Statistical Analysis); Lisa Buckingham
(Data Management).
Central Adjudication Committee: Dale Williams, Rajiv Gandhi, Matti Seppänen.
Data Safety Monitoring Board: Tim Ramsay (Chair), John Lee, Petteri Kousa.
Acknowledgements
Research grants were received from the following: Canadian Institutes of
Health Research (CIHR) (PI: OR Ayeni, Co-PI: M Bhandari), American Orthopaedic
Society for Sports Medicine (PI: OR Ayeni), Canadian Orthopaedic Foundation
(PI: OR Ayeni, Co-PI: M Bhandari), McMaster Surgical Associates (PI: OR Ayeni,
Co-PI: M Bhandari), and Hamilton Health Sciences Department of Surgery (PI:
OR Ayeni). Dr. Bhandari was also funded, in part, by a Canada Research Chair in
Musculoskeletal Trauma which is unrelated to the present study (McMaster
University, Hamilton, ON, Canada). The funding sources had no role in design or
conduct of the study; the collection, management, analysis, or interpretation of
the data; or the preparation, review, or approval of the manuscript. Dr. Olufemi
R Ayeni had full access to all of the data in the study and takes responsibility for
the integrity of the data and the accuracy of the data analysis.
FIRST Investigators
The following persons participated in or have Ethics Board approval to
participate in the FIRST trial at the time of submission of this manuscript:
McMaster University Medical Centre (Canada) – Olufemi R Ayeni, Nicole
Simunovic, Sarah Crouch, Maggie Hamel-Smith Grassby, Patricia Hoyeck,
Zakia Islam. Kingston General Hospital (Canada) – Gavin Wood. Odense
University Hospital (Denmark) – Uffe Jørgensen. Turku University Hospital
(Finland) – Matti Seppänen, Mika Junnila, Petri Virolainen, Mari Routapohja.
Hatanpää Hospital (Finland) - Raine Sihvonen, Marko Raivio, Pirjo Toivonen.
Kuopio University Hospital (Finland) - Antti Joukainen, Tommi Kääriäinen,
Elina Jalava. University of Helsinki (Finland) - Teppo Järvinen.
Received: 17 December 2014 Accepted: 12 February 2015
FIRST Investigators BMC Musculoskeletal Disorders  (2015) 16:64 Page 11 of 12References
1. Gosvig KK, Jacobsen S, Sonne-Holm S, Gebuhr P. The prevalence of
cam-type deformity of the hip joint: a survey of 4151 subjects of the
Copenhagen Osteoarthritis Study. Acta Radiol. 2008;49:436–41.
2. Hack K, Di Primio G, Rakhra K, Beaulé PE. Prevalence of cam-type femoroacetabular
impingement morphology in asymptomatic volunteers. J Bone Joint Surg Am.
2010;92:2436–44.
3. Kapron AL, Anderson AE, Aoki SK, Phillips LG, Petron DJ, Toth R, et al.
Radiographic prevalence of femoroacetabular impingement in collegiate football
players: AAOS Exhibit Selection. J Bone Joint Surg Am. 2011;93:e111(1–10).
4. Beck M, Kalhor M, Leunig M, Ganz R. Hip morphology influences the pattern of
damage to the acetabular cartilage: femoroacetabular impingement as a cause
of early osteoarthritis of the hip. J Bone Joint Surg (Br). 2005;87:1012–8.
5. Ganz R, Parvizi J, Beck M, Leunig M, Nötzli H, Siebenrock KA.
Femoroacetabular impingement: a cause for osteoarthritis of the hip. Clin
Orthop Relat Res. 2003;417:112–20.
6. Byrd JW, Jones KS. Arthroscopic management of femoroacetabular
impingement: minimum 2-year follow-up. Arthroscopy.
2011;27:1379–88.
7. Agricola R, Heijboer MP, Bierma-Zeinstra SM, Verhaar JA, Weinans H,
Waarsing JH. CAM impingement causes osteoarthritis of the hip: a nationwide
prospective cohort study (CHECK). Ann Rheum Dis. 2013;72:918–23.
8. Clohisy JC, Dobson MA, Robison JF, Warth LC, Zheng J, Liu SS, et al.
Radiographic structural abnormalities associated with premature, natural
hip-joint failure. J Bone Joint Surg Am. 2011;93(S2):3–9.
9. Colvin AC, Harrast J, Harner C. Trends in hip arthroscopy. J Bone Joint Surg
Am. 2012;94:e23.
10. Bozic KJ, Chan V, Valone 3rd FH, Feeley BT, Vail TP. Trends in hip arthroscopy
utilization in the United States. J Arthroplasty. 2013;28(S8):140–3.
11. Millennium Research Group. An evolution in keyhole surgery: arthroscopy
goes for the hip. IQ Industry Insight. 2009, 1–3. Ref Type: Pamphlet.
12. Kolata G. Hip procedure grows popular despite doubt. The New York Times. 15
Nov 2011. [http://www.nytimes.com/2011/11/16/health/hip-impingement-grows-
popular-but-remains-unproven.html?_r=0].
13. Clohisy JC, Knaus ER, Hunt DM, Lesher JM, Harris-Hayes M, Prather H. Clinical
presentation of patients with symptomatic anterior hip impingement. Clin
Orthop Relat Res. 2009;467:638–44.
14. Hoppe DJ, de Sa D, Simunovic N, Bhandari M, Safran MR, Larson CM, et al.
The learning curve for hip arthroscopy: a systematic review. Arthroscopy.
2014;30:389–97.
15. de Sa D, Urquhart N, Philippon M, Ye JE, Simunovic N, Ayeni OR. Alpha
angle correction in femoroacetabular impingement. Knee Surg Sports
Traumatol Arthrosc. 2014;22:812–21.
16. Hetaimish BM, Khan M, Crouch S, Simunovic N, Bedi A, Mohtadi N, et al.
Consistency of reported outcomes after arthroscopic management of
femoroacetabular impingement. Arthroscopy. 2013;29:780–7.
17. Ayeni OR, Chan K, Al-Asiri J, Chien T, Sprague S, Liew S, et al. Sources and
quality of literature addressing femoroacetabular impingement. Knee Surg
Sports Traumatol Arthrosc. 2013;21:415–9.
18. Ayeni OR, Naudie D, Crouch S, Adili A, Pindiprolu B, Chien T, et al.
Surgical indications for treatment for femoroacetabular impingement
with surgical hip dislocation. Knee Surg Sports Traumatol Arthrosc.
2013;21:1676–83.
19. Ayeni OR, Adamich J, Farrokhyar F, Simunovic N, Crouch S, Philippon MJ,
et al. Surgical management of labral tears during femoroacetabular
impingement surgery: a systematic review. Knee Surg Sports Traumatol
Arthrosc. 2014;22:756–62.
20. Ayeni OR, Belzile EL, Musahl V, Naudie D, Crouch S, Sprague S, et al. Results
of the PeRception of femOroaCetabular impingEment by Surgeons Survey
(PROCESS). Knee Surg Sports Traumatol Arthrosc. 2014;22:906–10.
21. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual
analogue scales as ratio scale measures for chronic and experimental pain.
Pain. 1983;17:45–56.
22. Larson CM, Giveans MR. Arthroscopic management of femoroacetabular
impingement: early outcomes measures. Arthroscopy. 2008;24:540–6.
23. Larson CM, Giveans MR. Arthroscopic debridement versus refixation of the
acetabular labrum associated with femoroacetabular impingement.
Arthroscopy. 2009;25:369–76.
24. Schenker ML, Martin R, Weiland DE, Philippon MJ. Current trends in hip
arthroscopy: a review of injury diagnosis, techniques and outcome scoring.
Curr Opin Orthop. 2005;16:89–94.25. Ware Jr J, Kosinski M, Keller SD. A 12-item short-form health survey:
construction of scales and preliminary tests of reliability and validity.
Med Care. 1996;34:220–33.
26. Griffin DR, Parsons N, Mohtadi NGH, Safran MR on behalf of the Multicenter
Arthroscopy of the Hip Outcomes Research Network (MAHORN). A short
version of the International Hip Outcome Tool (iHOT-12) for use in routine
clinical practice. Arthroscopy. 2012;28:611–8.
27. EuroQol Group. The EQ-5D. [http://www.euroqol.org/home.html].
28. Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P. The
Bristol Female Lower Urinary Tract Symptoms questionnaire: development
and psychometric testing. Br J Urol. 1996;77:805–12.
29. Donovan J, Abrams P, Peters TJ, Kay HE, Reynard J, Chapple C, et al. The
ICS-‘BPH’ study: the psychometric validity and reliability of the ICS male
questionnaire. Br J Urol. 1996;77:554–62.
30. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The
Female Sexual Function Index (FSFI): a multidimensional self-report
instrument for the assessment of female sexual function. J Sex Marital Ther.
2000;26:191–208.
31. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The
International Index of Erectile Function (IIEF): a multidimensional scale for
assessment of erectile dysfunction. Urology. 1997;49:822–30.
32. Tonnis D, Heinecke A. Current concepts review-Acetabular and femoral
anteversion: relationship with osteoarthritis of the hip. J Bone Joint Surg
Am. 1999;81:1747–70.
33. Zaltz I, Kelly BT, Larson CM, Leunig M, Bedi A. Surgical treatment of
femoroacetabular impingement: what are the limits of hip arthroscopy?
Arthroscopy. 2014;30:99–110.
34. Haynes S. Guyatt and Tugwell: Clinical Epidemiology: How to do Clinical
Practice Research. New York: Lipincott Williams and Wilkins; 2006.
35. Kelly BT, Weiland DE, Schenker ML, Philippon MJ. Arthroscopic labral repair
in the hip: surgical technique and review of the literature. Arthroscopy.
2005;21:1496–504.
36. Ayeni OR, Wong I, Chien T, Musahl V, Kelly BT, Bhandari M. Surgical
indications for arthroscopic management of femoroacetabular
impingement. Arthroscopy. 2012;28:1170–9.
37. Spencer-Gardner L, Eischen JJ, Levy BA, Sierra RJ, Engasser WM, Krych AJ. A
comprehensive five-phase rehabilitation programme after hip arthroscopy
for femoroacetabular impingement. Knee Surg Sports Traumatol Arthrosc.
2014;22:848–59.
38. Jensen MP, Karoly P. The measurement of clinical pain intensity: a
comparison of six methods. Pain. 1986;27:117–26.
39. Collins S, Moore A, McQuay H. The visual analog pain intensity scale: what is
moderate pain in millimeters? Pain. 1997;72:95–7.
40. Ho K, Spence J, Murphy M. Review of pain measurement tools. Ann Emerg
Med. 1996;27:427–31.
41. Kemp JL, Collins NJ, Roos EM, Crossley KM. Psychometric properties of
patient-reported outcome measures for hip arthroscopic surgery. Am J
Sports Med. 2013;41:2065–73.
42. Hinman RS, Dobson F, Takla A, O’Donnell J, Bennell KL. Which is the most
useful patient-reported outcome in femoroacetabular impingement? Test-
retest reliability of six questionnaires. Br J Sports Med. 2014;48:458–63.
43. Martin RL, Kelly BT, Philippon MJ. Evidence of validity for the hip outcome
score. Arthroscopy. 2006;22:1304–11.
44. Martin RL, Philippon MJ. Evidence of reliability and responsiveness for the
hip outcome score. Arthroscopy. 2008;24:676–82.
45. Martin RL, Philippon MJ. Evidence of validity for the hip outcome score in
hip arthroscopy. Arthroscopy. 2007;23:822–6.
46. Throborg K, Roos EM, Bartels EM, Petersen J, Hölmich P. Validity, reliability
and responsiveness of patient-reported outcome questionnaires when
assessing hip and groin disability: a systematic review. Br J Sports Med.
2010;44:1186–96.
47. Mohtadi NGH, Griffin DR, Pedersen ME, Chan D, Safran MR, Parsons N, et al. The
development and validation of a self-administered quality-of-life outcome measure
for young, active patients with symptomatic hip disease: the International Hip
Outcome Tool (iHOT-33). Arthroscopy. 2012;28:595–610.
48. Bosch JL, Hunink MG. Comparison of the Health Utilities Index Mark 3 (HUI3)
and the EuroQol EQ-5D in patients treated for intermittent claudication. Qual
Life Res. 2000;9:591–601.
49. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related
quality of life in rheumatoid arthritis: validity, responsiveness and reliability
of EuroQol (EQ-5D). Br J Rheumatol. 1997;36:551–9.
FIRST Investigators BMC Musculoskeletal Disorders  (2015) 16:64 Page 12 of 1250. Byrd JW. Complications associated with hip arthroscopy. In: Operative
Arthroscopy. New York: Thieme; 1998. p. 171–6.
51. Papvasiliou AV, Bardakos NV. Complications of arthroscopic surgery of the
hip. Bone Joint Res. 2012;1:131–7.
52. Labat JJ, Riant T, Robert R, Amarenco G, Lefaucheur JP, Rigaud J. Diagnostic
criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes
criteria). Neurourol Urodyn. 2008;27:306–10.
53. Harris JD, McCormick FM, Abrams GD, Gupta AK, Ellis TJ, Bach Jr BR, et al.
Complications and reoperations during and after hip arthroscopy: a
systematic review of 92 studies and more than 6000 patients. Arthroscopy.
2013;29:589–95.
54. Sarramon JP, Malavaud B, Braud F, Bertrand N, Vaessen C, Rischmann P.
Evaluation of male sexual function after deep dorsal vein arterialization of
the penis. J Urology. 2001;166:576–80.
55. Ng VY, Arora N, Best TM, Pan X, Ellis TJ. Efficacy of surgery for
femoroacetabular impingement: a systematic review. Am J Sports Med.
2010;38:2337–45.
56. Malviya A, Stafford GH, Villar RN. Impact of arthroscopy of the hip for
femoroacetabular impingement on quality of life at a mean follow-up of
3.2 years. J Bone Joint Surg (Br). 2012;94:466–70.
57. Philippon MJ, Ejnisman L, Ellis HB, Briggs KK. Outcomes 2 to 5 years
following hip arthroscopy for femoroacetabular impingement in the patient
aged 11 to 16 years. Arthroscopy. 2012;28:1255–61.
58. Nötzli HP, Wyss TF, Stoecklin CH, Schmid MR, Treiber K, Hodler J. The
contour of the femoral head-neck junction as a predictor for the risk of
anterior impingement. J Bone Joint Surg (Br). 2002;84:556–60.
59. Clohisy JC, Carlisle JC, Beaulé PE, Kim YJ, Trousdale RT, Sierra RJ, et al. A
systematic approach to the plain radiographic evaluation of the young
adult hip. J Bone Joint Surg Am. 2008;90(S4):47–66.
60. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related
quality of life: the remarkable universality of half a standard deviation. Med
Care. 2003;41:582–92.
61. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New
Jersey: Lawrence Erlbaum Associates; 1988.
62. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36).
I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
63. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York: John
Wiley & Sons; 1987.
64. Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, et al. A
tutorial on sensitivity analyses in clinical trials: the what, why, when and
how. BMC Med Res Methodol. 2013;13:92.
65. Agricola R, Waarsing JH, Thomas GE, Carr AJ, Reijman M, Bierma-Zeinstra
SM, et al. CAM impingement: defining the presence of a CAM deformity by
the alpha angle: data from the CHECK cohort and Chingford cohort.
Osteoarthritis Cartilage. 2014;22:218–25.
66. Agricola R, Waarsing JH, Arden NK, Carr AJ, Bierma-Zeinstra SM, Thomas GE,
et al. CAM impingement of the hip-a risk factor for hip osteoarthritis. Nat
Rev Rheumatol. 2013;9:630–4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
